NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.

Authors :: Thompson JA
Schneider BJ
Brahmer J
Andrews S
Armand P
Bhatia S
Budde LE
Costa L
Davies M
Dunnington D
Ernstoff MS
Frigault M
Kaffenberger BH
Lunning M
McGettigan S
McPherson J
Mohindra NA
Naidoo J
Olszanski AJ
Oluwole O
Patel SP
Pennell N
Reddy S
Ryder M
Santomasso B
Shofer S
Sosman JA
Wang Y
Weight RM
Johnson-Chilla A
Zuccarino-Catania G
Engh A
Source :: Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2020 Mar; Vol. 18 (3), pp. 230-241.
Publication Year :: 2020
Abstract: The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide interdisciplinary guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy. These NCCN Guidelines Insights describe symptoms that may be caused by an irAE and should trigger further investigation, and summarize the NCCN Management of Immunotherapy-Related Toxicities Panel discussions for the 2020 update to the guidelines regarding immune checkpoint inhibitor-related diarrhea/colitis and cardiovascular irAEs.

Subjects :: Humans
Immunotherapy methods
Antineoplastic Agents, Immunological adverse effects
Neoplasms drug therapy

Full Text Access

Tools